The 20 Best PIK3CA-Related Overgrowth Spectrum Doctors Near Me in Maryland, US

Dr. Antonio Wolff is internationally recognized for his work on breast cancer biomarkers, including HER2. As a practicing oncologist and clinical translational researcher, his research has been pivotal to improve the quality of breast cancer biomarker testing in breast cancer, including HER2 and estrogen receptor testing. Among his leadership accomplishments is ensuring that sophisticated laboratory findings are translated into improved clinical care in breast cancer. He is a Fellow of the American Society of Clinical Oncology (ASCO), a Komen Scholar and a Breast Cancer Research Foundation investigator. He has served as associate editor for Journal of Clinical Oncology, and serves on the National Comprehensive Cancer Network (NCCN) Guideline Steering Committee. He is a leader of the Translational Breast Cancer Research Consortium (TBCRC), and one of the principal investigators of the Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (EVOLVE) in Metastatic Breast Cancer, which was one of the three disease groups recently awarded by ARPA-H to conduct innovative trials using Advanced Analysis for Precision Cancer Therapy (ADAPT). After many years of service as Breast Committee Chair in the ECOG-ACRIN Clinical Trial Network of the National Cancer Institute (NCI), he was elected in 2024 as Co-Chair of the NCI Breast Cancer Steering Committee and appointed to the international steering committee of the Oxford Overview Collaborative, which are positions aimed at advancing clinical trials in breast cancer. At Johns Hopkins, he is an elected member of the Miller Coulson Academy of Clinical Excellence and was honored during the 125th Anniversary Living the Hopkins Mission celebrations of the JHU School of Medicine. Dr. Wolff is rated as an Advanced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, and Inflammatory Breast Cancer. Dr. Wolff is board certified in American Board Of Internal Medicine.

Fang Wang is a Holistic Medicine provider practicing medicine in Rockville, Maryland. Ms. Wang is rated as a Distinguished provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 10 other conditions, according to our data. Her clinical expertise encompasses PIK3CA-Related Overgrowth Spectrum, Anencephaly, Periodontitis, Endoscopy, and Vitrectomy. Ms. Wang is currently accepting new patients.

Dr. Jaqueline Weissman is an assistant professor in the Department of Neurology, Kennedy Krieger Institute, Department of Pediatrics Johns Hopkins Hospital and Institute of Genomic Medicine at Johns Hopkins Hospital. She is also director of the Center for Tuberous Sclerosis and Related Disorder at Kennedy Krieger Institute. She focuses on genetic and epigenetic causes of neurodevelopmental disorders - particularly intellectual disability - and how specific genetic and epigenetic changes lead to specific neuroanatomic, neurophysiologic and cognitive phenotypes. She is also interested in developing specific cognitive profiles in genetic syndromes as potential outcome measures for trials and to help localize deficits. Currently most of her research is centered around Kabuki Syndrome. Dr. Weissman received her B.A. with. Dr. Harris is rated as an Advanced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 10 other conditions, according to our data. Her clinical expertise encompasses Tuberous Sclerosis, Tuberous Sclerosis Complex, Parkes Weber Syndrome, and Microcephaly Deafness Syndrome. Dr. Harris is board certified in American Board Of Psychiatry And Neurology.

Thomas Darling is a Dermatologist practicing medicine in Bethesda, Maryland. Dr. Darling is rated as an Advanced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Mosaicism, Acromicric Dysplasia, PIK3CA-Related Overgrowth Spectrum, and Linear Hamartoma Syndrome.

Daniel Zabransky is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Zabransky is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 1 other condition, according to our data. His clinical expertise encompasses HER-2 Positive Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Melanoma, and Breast Cancer. Dr. Zabransky is board certified in American Board Of Internal Medicine.

Julie R. Brahmer, M.D., M.Sc. is the Director of the Thoracic Oncology Program, Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Marilyn Meyerhoff Professor in Thoracic Oncology. She also directs the Kimmel Cancer Center on the Johns Hopkins Bayview campus and is co-principal investigator on Johns Hopkins' National Clinical Trials Network. Dr. Brahmer received her undergraduate degree in Chemistry and Philosophy in 1989 from the Creighton University in Omaha, Nebraska and went on to receive her medical degree from the University of Nebraska Medical Center College of Medicine in 1993. Completing her internship and residency in Internal Medicine at the University of Utah, Dr. Brahmer later became the Chief Medical Resident until moving to Baltimore to complete her fellowship in Medical Oncology at the Kimmel Cancer Center at Johns Hopkins. Dr. Brahmer is an active clinical leader in the treatment of lung cancer and mesothelioma. She leads the organization of the multidisciplinary thoracic malignancy conference whose members meet weekly to discuss thoracic malignancy cases that need a multidisciplinary review/approach. Dr. Brahmer's research and clinical practice focuses on the development of new therapies for the treatment and prevention of lung cancer and mesothelioma. Dr. Brahmer's research interests include leading early phase immunotherapy trials of anti-PD-1 antibodies, international phase III studies of immunotherapies in lung cancer and investigator-initiated trials evaluating epigenetic therapies in combination with immunotherapies. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group (ECOG) Thoracic Committee and Cancer Prevention Steering Committee. She is one of the founding Board members for the National Lung Cancer Partnership (formerly Women Against Lung Cancer). Within the National Lung Cancer Partnership, she currently serves as a member and the Chairman of the Scientific Executive Committee. She is also on the medical advisory board of the Lung Cancer Research Fund and the Mesothelioma Applied Research Foundation. Dr. Brahmer is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 13 other conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). Dr. Brahmer is board certified in American Board Of Internal Medicine.

Dr. Richard Southard’s specialty is in pediatric radiology, with more than 25 years of experience in private practice and hospital settings. He joins Johns Hopkins from Phoenix Children’s Hospital, where he is vice chief of Radiology Operations. Previously, he served as a pediatric radiologist, partner and president of Radiology Consultants North Dallas, a Texas-based private practice group. He earned his medical degree from The Ohio State University before going on to an internship and residency in pediatric medicine at Nationwide Children’s Hospital, followed by a diagnostic radiology residency at The University of Pittsburgh Medical Center and fellowship in pediatric radiology at Pittsburgh Children’s Hospital. Dr. Southard’s research has focused on CT radiation dose reduction, imaging of congenital heart disease, implementation and validation of iterative reconstruction noise reduction techniques and dual-energy spectral CT applications in children. He joined the pediatric radiology faculty in February 2023 and will be working remotely from Arizona. Dr. Southard is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Tracheobronchopathia Osteoplastica, Bronchogenic Cyst, Dextrocardia, and Collins Pope Syndrome. Dr. Southard is board certified in American Board Of Radiology.

Dr. Nilofer S. Azad is Professor of Oncology at Johns Hopkins University School of Medicine and serves as the Associate Cancer Center Director for Clinical Research for the Johns Hopkins Sidney Kimmel Cancer Center. Dr. Azad earned her medical degree and completed a residency in internal medicine at Baylor College of Medicine in Houston, Texas. She then completed a fellowship in oncology and hematology at the National Institute of Health's National Cancer Institute in Bethesda, Maryland where she served as chief fellow. Dr. Azad’s research focused on early phase drug development and the intersection of moving exciting laboratory findings into patients for new treatment options Dr. Azad joined the faculty at the Kimmel Cancer Center in 2008. Dr. Azad’s clinical expertise is in cancers of the gastrointestinal tract, with a concentration in colorectal cancer, cholangiocarcinoma and pancreaticobiliary tract cancer. Her research efforts are dedicated to developing new drug combinations for patients with advanced cancer. In particular, Dr. Azad’s laboratory and clinical trials explore epigenetic therapy in combination with chemotherapy and immunotherapy to improve survival for patients, as well as molecularly targeted drugs. She is an active clinical trialist, leading multiple clinical trials of molecularly targeted agents for advanced cancer patients. Dr. Azad has received numerous grants for her work from entities such as the NCI (National Cancer Center), American Cancer Society, American Society of Clinical Research, Breakthrough Cancer Foundation, the Lustgarten Foundation, The Gateway Foundation, and the National Comprehensive Cancer Network, among others. She served as Principal for Johns Hopkins on the AACR Stand Up 2 Cancer Colorectal Cancer Dream Team and is a member of the Stand Up 2 Cancer Epigenetics Dream Team, leading the GI cancer initiatives for the group. Dr. Azad is a national leader in GI cancer, including serving as a member of the national NCI Colon Cancer Task Force and as Co-Chair of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. She has a presidential appointment to the National Cancer Advisory Board. Dr. Azad is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 18 other conditions, according to our data. Her clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Pancreatic Cancer, Hepato-Pancreato-Biliary Surgery, and Colonoscopy. Dr. Azad is board certified in American Board Of Internal Medicine.

Dr. Lam treats patients with lung cancer, esophageal cancer, mesothelioma, and other thoracic cancers. He directs the Thoracic Oncology Clinical Research Program and the Esophageal Cancer Research Program at Johns Hopkins. Dr. Lam is a clinical and translational researcher with a focus on cancer genomics, liquid biopsies, and novel immunotherapies such as vaccines and cell therapies. He has been recognized with a Conquer Cancer Foundation/ASCO Career Development Award, an LCFA/IASLC/BMS Young Investigator Award, and as a Gilead Research Scholar. Dr. Lam is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Hepatectomy, and Hepato-Pancreato-Biliary Surgery.

Dr. Santa-Maria completed his oncology training at Johns Hopkins, and has been focused on caring for patients with breast cancer since then. He works as both a primary oncologist and consultant for patients with all types and stages of breast cancer. His research interest is in developing new types of treatment for patients with breast cancer using immunotherapy. Dr. Santa is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, and Paget Disease of the Breast. Dr. Santa is board certified in American Board Of Internal Medicine.

Dr. Samuel Denmeade is the R. Dale Hughes Professor of Oncology and Urology at the Johns Hopkins University School of Medicine and Director of the Genitourinary Oncology Division for the Johns Hopkins Kimmel Cancer Center. He also has appointments in the Department of Pharmacology and Molecular Sciences and Department of Biomolecular Engineering. His areas of clinical expertise include bladder cancer, kidney cancer, prostate cancer and testicular cancer. Dr. Denmeade earned his M.D. from the Columbia College of Physicians and Surgeons of Columbia University. He completed his residency at the University of Chicago. He performed a fellowship in oncology at The Johns Hopkins Hospital and a fellowship in medical oncology at the Johns Hopkins University School of Medicine. His research interests include prostate cancer, bipolar androgen therapy, clinical trials and targeted drug development. Dr. Denmeade has published over 200 papers in the area of prostate cancer research. He has received extensive funding from the NIH, the Department of Defense Prostate Cancer Research Fund and the Prostate Cancer Foundation. He is the Editor-in-Chief of the medical journal The Prostate. Dr. Denmeade is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 9 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Prostatectomy. Dr. Denmeade is board certified in American Board Of Internal Medicine.

Dr. James Segars is director of the Division of Reproductive Science and Women’s Health Research and a professor in the Johns Hopkins Department of Gynecology and Obstetrics. He leads the Howard W. and Georgeanna Seegar Jones Laboratory of Reproductive Sciences and Women's Health Research, where he and his team focus on endometriosis, uterine fibroids, and reproductive and ovarian disorders. Dr. Segars received his undergraduate degree from Duke University and earned his M.D. from Duke University School of Medicine. He completed his residency in obstetrics and gynecology and a clinical fellowship in reproductive endocrinology at Vanderbilt University. Dr. Segars performed a postdoctoral fellowship at the Laboratory of Molecular Growth Regulation at the National Institute of Child Health and Human Development. He joined the Johns Hopkins faculty in 2015. Before coming to Johns Hopkins, Dr. Segars was head of the Unit on Reproductive Endocrinology and Infertility at the National Institute of Child Health and Human Development and a professor in the Department of Obstetrics and Gynecology at the Uniformed Services University of the Health Sciences. Dr. Segars has published more than 160 peer-reviewed research articles and serves on the editorial boards of Reproductive Sciences, Molecular Human Reproduction, Seminars in Reproductive Medicine, and Fertility and Sterility. Dr. Segars is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Uterine Fibroids, Infertility, Endometriosis, Adenomyosis, and Hysterectomy. Dr. Segars is board certified in American Board Of Obstetrics And Gynecology.

Dr. Jessica Tao is a medical oncologist specializing in the care of patients with breast cancer. She co-leads the Cancer Center-wide Johns Hopkins Molecular Tumor Board, a multidisciplinary effort to interpret complex genomic information and provide individualized, precision oncology treatment recommendations to patients with all types of cancer. In addition to caring for patients, Dr. Tao maintains an active clinical-translational research program dedicated to developing novel treatments to patients with advanced cancer. Her expertise and research focuses on finding and targeting the molecular changes that drive a person’s tumor and understanding novel mechanisms of response and resistance to targeted therapies. A second major area of her research is development and application of “liquid biopsy” technologies, including circulating tumor DNA, in the early detection and disease monitoring of breast cancer. Dr. Tao is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 4 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Angiosarcoma. Dr. Tao is board certified in American Board Of Internal Medicine.

Dr. Comi graduated from SUNY Buffalo School of Medicine and received her training in pediatrics at the Children's Hospital of Buffalo and her child neurology training at Johns Hopkins Medicine. Her clinical specialization is in the treatment of the neurological aspects of Sturge-Weber syndrome and other disorders related to capillary malformation. Dr. Comi's clinical research interests focus on improving the early diagnosis and treatment of brain involvement in Sturge-Weber syndrome in order to prevent ischemic brain injury in affected infants and young children, and on studies to understand what causes Sturge-Weber syndrome. Her laboratory research work deals with the pathogenesis of Sturge-Weber syndrome, recently shown to be caused by a somatic mutation, and on developing new drug targets, screening assays, models and therapeutic strategies for Sturge-Weber syndrome. Her lab group also works on developing better neuroprotective and neuroregenerative responses to brain injury resulting from impaired blood flow to the brain. Dr. Comi is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 22 other conditions, according to our data. Her clinical expertise encompasses Sturge-Weber Syndrome, Parkes Weber Syndrome, Stork Bite, Epilepsy in Children, and Endovascular Embolization. Dr. Comi is board certified in American Board Of Psychiatry And Neurology.

Padma Rajagopal is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Rajagopal is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 1 other condition, according to our data. Her clinical expertise encompasses Breast Cancer, Familial Prostate Cancer, Triple-Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Gastrostomy. Dr. Rajagopal is board certified in American Board Of Preventive Medicine and American Board Of Internal Medicine.

Dr. Elham Afghani is an assistant professor of Medicine at the Johns Hopkins University School of Medicine. She joins us from Cedars Sinai Medical Center in Los Angeles. She received her medical degree from University of California, Irvine. She completed her internal medicine residency as well as an extra year as chief resident at the University of California, Irvine, Medical Center. She then completed her gastroenterology and hepatology fellowship with additional training in pancreatic diseases at the Johns Hopkins University School of Medicine. With a unique specialization in pancreatic disease, she has participated in numerous research projects at the Cedars Sinai division of pancreatico-biliary diseases and was involved in a U01 Consortium for the study of chronic pancreatitis, diabetes and pancreatic cancer. Dr. Afghani’s areas of expertise include acute and chronic pancreatitis, pancreatic cysts and pancreatic exocrine insufficiency. She is an accomplished researcher with multiple publications in prestigious peer-reviewed journals as well as presentations at national meetings. Dr. Afghani is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. She is also highly rated in 9 other conditions, according to our data. Her clinical expertise encompasses Hereditary Pancreatitis, Acute Pancreatitis, Chronic Pancreatitis, Endoscopy, and Lithotripsy. Dr. Afghani is board certified in American Board Of Internal Medicine.

Eric Christenson is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Christenson is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Pancreatic Ductal Adenocarcinoma. Dr. Christenson is board certified in American Board Of Internal Medicine.

Dr. Matthias Holdhoff is a medical oncologist and co-director of the Brain Cancer Disease Group at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of oncology, neurology and neurological surgery at Johns Hopkins University School of Medicine. Dr. Holdhoff’s expertise is in primary brain cancers and central nervous system lymphomas. He earned his medical degree from Freie Universität Berlin, received his doctorate degree at Charité University Medicine Berlin. Dr. Holdhoff completed residency training in internal medicine at Johns Hopkins Bayview Medical Center, followed by a fellowship in medical oncology at Johns Hopkins Hospital with research training at the Ludwig Center for Cancer Genetics and Therapeutics (Kinzler-Vogelstein lab). As a clinical investigator in neuro-oncology, his research is focused on novel trials and translational biomarker studies in malignant gliomas and primary central nervous system lymphomas. He has led and contributed to numerous clinical trials, publications and presentations. Dr. Holdhoff serves as the director of the solid tumor inpatient service at the Sidney Kimmel Comprehensive Cancer Center. He is passionately involved in mentoring and teaching of fellows, residents and students. He is the director of the UCNS-certified neuro-oncology fellowship program at Johns Hopkins, and he is a teaching attending physician for the Osler internal medicine residency program. Dr. Holdhoff is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Glioma, Glioblastoma, Astrocytoma, and Brain Tumor. Dr. Holdhoff is board certified in American Board Of Internal Medicine.

James Stuart Ferriss is an associate professor in the Johns Hopkins Department of Gynecology and Obstetrics and director of the F.J. Montz Gynecologic Oncology Fellowship Program. He is an expert in the care of women with cancers of the uterus, cervix, vulva, vagina, fallopian tubes and ovaries. Dr. Ferriss is passionate about minimally invasive approaches to surgery and has extensive experience with robotic surgery. Dr. Ferriss received his undergraduate and medical degrees from Louisiana State University. He then completed his residency in obstetrics and gynecology at the University of Texas Southwestern Medical Center and his fellowship in gynecologic oncology at the University of Virginia. Prior to joining Johns Hopkins, Dr. Ferriss was associate professor in the departments of women’s health and oncology at the University of Texas at Austin Dell Medical School. Before that, he was assistant professor in the department of obstetrics, gynecology and reproductive sciences at Temple University in Philadelphia. Dr. Ferriss’ research is focused on innovations in surgical and clinical education. Dr. Ferriss serves on a variety of boards and is a member of the Society of Gyneocologic Oncology, Mid-Atlantic Gynecologic Oncology Society, American Society of Clinical Oncology, the American College of Surgeons and the American Congress of Obstetricians and Gynecologists. He has been recognized with several awards and honors, including being named a top doctor for outstanding patient care. Dr. Ferriss’ passion for getting to know each of his patients’ values and personal treatment goals and empowering them to be active participants in their treatment defines his approach to patient care. Dr. Ferriss has special interest in supporting his patients through the entire arc of their cancer care from diagnosis to surgery, chemotherapy, and survivorship and palliative care. Videos Dr. Stuart FerrissGynecologic Oncologist Contact for Research Inquiries 600 N. Wolfe St Phipps 281 Baltimore, MD 21287 Research Summary Dr. Ferriss’ research currently focuses on increasing the diversity of patients recruited to clinical trials by understanding the factors and circumstances that prevent some patients from participating. He is also focused on innovations in surgical and clinical education. Dr. Ferriss is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Neuroendocrine Carcinoma of the Cervix, Cervical Cancer, Ovarian Cancer, Oophorectomy, and Lymphadenectomy. Dr. Ferriss is board certified in American Board Of Obstetrics And Gynecology.

Dr. Dalton is an Assistant Professor of Oncology at The Johns Hopkins University School of Medicine. He is active in the Division of Hematology Malignancies, Leukemia Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Dr. Dalton has expertise in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), and acute lymphoblastic leukemia (ALL). Dr. Dalton received a combined M.D./Ph.D. degree through the Medical Scientist Training Program at Emory University School of Medicine. He completed a residency in internal medicine and a fellowship in medical oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 2017. Dr. Dalton is a member of the American Society of Hematology and the American Society of Clinical Oncology. Dr. Dalton's primary research is to better understand the genetic events that drive MDS and AML and to develop new therapeutic approaches against these diseases. Dr. Dalton is rated as an Experienced provider by MediFind in the treatment of PIK3CA-Related Overgrowth Spectrum. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Aspiration, and Pancreaticoduodenectomy. Dr. Dalton is board certified in American Board Of Internal Medicine.